

Innovation in HR+, HER2– Advanced Breast Cancer and the Emerging Role of Biomarkers

2 May 2019 | 12:00 – 13:00 | Maritim Hotel Berlin, Berlin Hall

Chair and Moderator:

Diana Lüftner [Germany]

Faculty:

Peter Fasching [Germany]

Nick Turner [UK]

Learning Objectives

- Discuss recent data on treatment combinations for HR+, HER2– ABC, including analyses in select subpopulations
- Provide expert insights on the evolving role of biomarkers, including *PIK3CA* and relevant testing in the management of HR+, HER2-ABC
- Focus on the importance of patient care to maximize treatment outcomes and quality of life for HR+, HER2-ABC on targeted therapies

	TOPIC	FACULTY
12:00-12:05	Welcome and Introduction	Chair: Diana Lüftner
12:05-12:25	Expanding the Evidence Base for CDK4/6 Inhibitors	Diana Lüftner
12:25-12:35	The Advancing Role of PI3K Inhibitors	Peter Fasching
12:35-12:50	Considerations for PIK3CA Mutations: An Interactive Discussion	Nick Turner
12:50-13:00	Audience Q&A	All Faculty
13:00	Concluding Remarks	Chair: Diana Lüftner

This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities.

This program and/or material was developed for use outside of the US, intended for non-US HCPs, and is to be used in accordance with local laws and regulations.